ArticleBritish journal of cancer2026

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab.

Judith D J Verdonk et al.PubMed ↗Publisher ↗

No numbers read from the abstract.